

Hartmut Derendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9103850/publications.pdf>

Version: 2024-02-01

398
papers

17,677
citations

14614

66
h-index

22764

112
g-index

415
all docs

415
docs citations

415
times ranked

15971
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 492-499.	1.0	510
2	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 601-607.	1.3	448
3	Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2006, 45, 649-663.	1.6	386
4	How Important Are Gender Differences in Pharmacokinetics?. <i>Clinical Pharmacokinetics</i> , 2002, 41, 329-342.	1.6	365
5	Tissue concentrations: do we ever learn?. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 235-237.	1.3	333
6	Absorption, Metabolism, and Antioxidant Effects of Pomegranate (<i>Punica granatum</i> L.) Polyphenols after Ingestion of a Standardized Extract in Healthy Human Volunteers. <i>Journal of Agricultural and Food Chemistry</i> , 2006, 54, 8956-8961.	2.4	299
7	Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. , 1999, 16, 176-185.		275
8	Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1107-1122.	1.6	267
9	Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 369-377.	1.4	262
10	Pharmacokinetics and Bioavailability of Herbal Medicinal Products. <i>Phytomedicine</i> , 2002, 9, 1-33.	2.3	253
11	Pharmacokinetic and Pharmacodynamic Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 1998, 35, 49-64.	1.6	243
12	Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 313-317.	2.3	238
13	Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1441-1453.	1.4	237
14	Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. <i>European Respiratory Journal</i> , 2006, 28, 1042-1050.	3.1	212
15	Protein Binding: Do We Ever Learn?. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3067-3074.	1.4	212
16	Inhaled Corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, S1-S40.	1.5	211
17	Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. <i>Clinical Pharmacokinetics</i> , 2010, 49, 379-396.	1.6	210
18	Pharmacokinetics of Anthocyanins and Antioxidant Effects after the Consumption of Anthocyanin-Rich Açaí Juice and Pulp (<i>Euterpe oleracea</i> Mart.) in Human Healthy Volunteers. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 7796-7802.	2.4	202

#	ARTICLE	IF	CITATIONS
19	Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. <i>Phytomedicine</i> , 2005, 12, 28-38.	2.3	195
20	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, S440-S446.	1.5	193
21	Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1083-1105.	1.0	193
22	Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1292-1300.	2.7	192
23	Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1997, 35, 401-13.	0.3	183
24	Duffy antigen modifies the chemokine response in human endotoxemia. <i>Critical Care Medicine</i> , 2008, 36, 159-165.	0.4	159
25	Hyperforin in St. John's wort drug interactions. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 225-233.	0.8	156
26	Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 285-290.	1.1	152
27	Microdialysis in peripheral tissues. <i>Advanced Drug Delivery Reviews</i> , 2000, 45, 189-216.	6.6	144
28	Pharmacokinetics and Oral Bioavailability of Hydrocortisone. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 473-476.	1.0	140
29	Gender differences in pharmacokinetics and pharmacodynamics. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1999, 37, 529-47.	0.3	139
30	Systemic Availability and Pharmacokinetics of Thymol in Humans. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 731-737.	1.0	135
31	Pharmacokinetic/Pharmacodynamic Studies in Drug Product Development. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 18-31.	1.6	130
32	Pharmacokinetic/pharmacodynamic modeling in drug research and development. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1399-418.	1.0	122
33	Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents. <i>Clinical Microbiology Reviews</i> , 2013, 26, 274-288.	5.7	121
34	Receptor-Based Pharmacokinetic/Pharmacodynamic Analysis of Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 115-123.	1.0	120
35	Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. <i>Respiratory Medicine</i> , 1997, 91, 22-28.	1.3	110
36	Variation of Flavonoids and Furanocoumarins in Grapefruit Juices: A Potential Source of Variability in Grapefruit Juice-Drug Interaction Studies. <i>Journal of Agricultural and Food Chemistry</i> , 2006, 54, 249-255.	2.4	108

#	ARTICLE	IF	CITATIONS
37	Microdialysis. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 211-219.	0.8	106
38	Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 277-284.	1.3	101
39	Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 302-305.	1.0	100
40	Grapefruit-Drug Interactions: Can Interactions With Drugs Be Avoided?. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1390-1416.	1.0	100
41	How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 356-363.	3.5	98
42	Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3994-4000.	1.4	97
43	Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 881-892.	1.0	96
44	Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1286.e1-1286.e7.	2.8	96
45	Comparative Pharmacology, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Inhaled Glucocorticosteroids. <i>Immunology and Allergy Clinics of North America</i> , 2005, 25, 469-488.	0.7	94
46	Pharmacokinetics and bioavailability of the flavonol quercetin in humans. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1999, 37, 219-33.	0.3	93
47	Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P ₁ receptor modulator, in the first-in-human study. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 888-896.	1.1	92
48	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 355-358.	1.1	91
49	Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 837-853.	1.0	90
50	Grapefruit Juice—Drug Interactions: Grapefruit Juice and Its Components Inhibit P-glycoprotein (ABCB1) Mediated Transport of Talinolol in Caco-2 Cells. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2808-2817.	1.6	90
51	Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 822-829.	1.3	85
52	Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 37-47.	1.0	83
53	In vitro pharmacodynamic models to determine the effect of antibacterial drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 186-201.	1.3	80
54	Desensitization of Brain Opiate Receptor Mechanisms by Gonadal Steroid Treatments that Stimulate Luteinizing Hormone Secretion*. <i>Endocrinology</i> , 1988, 122, 2718-2726.	1.4	79

#	ARTICLE	IF	CITATIONS
55	Interstitial tissue concentrations of cefpodoxime. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 19-22.	1.3	79
56	Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 1-7.	1.1	79
57	Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 62-67.	1.1	76
58	AAPS-FDA Workshop White Paper: Microdialysis Principles, Application, and Regulatory Perspectives. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 589-603.	1.0	76
59	PK/PD: new insights for antibacterial and antiviral applications. <i>Current Opinion in Pharmacology</i> , 2008, 8, 549-556.	1.7	76
60	PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 239-245.	1.4	76
61	Microdialysis for pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. <i>Current Opinion in Pharmacology</i> , 2005, 5, 495-499.	1.7	75
62	Pharmacokinetics of triamcinolone acetonide and its phosphate ester. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 85-89.	0.8	73
63	Pharmacokinetics of dexamethasone and its phosphate ester. <i>Biopharmaceutics and Drug Disposition</i> , 1987, 8, 205-212.	1.1	71
64	Clinical Microdialysis in Skin and Soft Tissues: An Update. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 351-364.	1.0	70
65	Characterizing the Effects of Caspofungin on <i>Candida albicans</i> , <i>Candida parapsilosis</i> , and <i>Candida glabrata</i> Isolates by Simultaneous Time-Kill and Postantifungal-Effect Experiments. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2569-2572.	1.4	69
66	Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 231-235.	1.1	69
67	Drugs in space: Pharmacokinetics and pharmacodynamics in astronauts. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S2-S8.	1.9	69
68	Pharmacokinetic Studies of Florfenicol in Koi Carp and Threespot Gourami <i>Trichogaster trichopterus</i> after Oral and Intramuscular Treatment. <i>Journal of Aquatic Animal Health</i> , 2005, 17, 129-137.	0.6	68
69	Tobacco smoke exposure induces nicotine dependence in rats. <i>Psychopharmacology</i> , 2010, 208, 143-158.	1.5	68
70	A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 733-739.	1.3	67
71	Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins. <i>Journal of Pharmaceutical Sciences</i> , 1988, 77, 981-985.	1.6	65
72	Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. <i>European Journal of Clinical Pharmacology</i> , 1998, 53, 459-467.	0.8	65

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic Herb-Drug Interactions: Are Preventive Screenings Necessary and Appropriate?. <i>Planta Medica</i> , 2004, 70, 784-791.	0.7	65
74	Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. <i>European Journal of Medical Research</i> , 2010, 15, 533.	0.9	65
75	Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L- <i>NAME</i> in humans. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 539-544.	1.1	64
76	Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 845-850.	1.0	64
77	Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline. <i>Clinical Pharmacokinetics</i> , 2009, 48, 575-584.	1.6	64
78	When is Protein Binding Important?*. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3458-3467.	1.6	64
79	Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 1998, 21, 444-452.	0.6	63
80	Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. <i>Pharmaceutical Research</i> , 1996, 13, 91-96.	1.7	62
81	Pharmacodynamic activity of the lantibiotic MU1140. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 70-74.	1.1	62
82	Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 782-789.	1.0	60
83	Antimicrobial tissue concentrations. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 599-613.	1.9	59
84	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisolone. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 27-37.	1.6	59
85	Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 431-438.	1.1	57
86	Kinetics of methylprednisolone and its hemisuccinate ester. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 502-507.	2.3	56
87	Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 916-925.	1.0	55
88	Comparison of Plasma and Free Tissue Levels of Ceftriaxone in Rats by Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 52-56.	1.6	53
89	Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 439-444.	1.9	53
90	Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 632-636.	1.3	53

#	ARTICLE	IF	CITATIONS
91	Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 51-54.	1.1	53
92	Clinical microdialysis: Current applications and potential use in drug development. <i>TrAC - Trends in Analytical Chemistry</i> , 2006, 25, 674-680.	5.8	52
93	Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1187-1193.	1.0	51
94	Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 938-941.	1.0	51
95	Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 120-129.	1.1	51
96	HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1986, 4, 197-206.	1.4	50
97	Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2521-2528.	1.6	50
98	Population Kinetics, Efficacy, and Safety of Dichloroacetate for Lactic Acidosis Due to Severe Malaria in Children. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 386-396.	1.0	49
99	Sex related differences on valproic acid pharmacokinetics after oral single dose. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 479-486.	0.8	49
100	Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions. <i>Clinical Pharmacokinetics</i> , 2014, 53, 205-212.	1.6	49
101	Effect of fat distribution on the pharmacokinetics of cortisol in obesity. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1998, 36, 501-5.	0.3	49
102	Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. <i>Pharmaceutical Research</i> , 1995, 12, 1096-1100.	1.7	48
103	Population Pharmacokinetics of Intramuscular Quinine in Children with Severe Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1803-1809.	1.4	48
104	Effect of Grapefruit Juice, Naringin, Naringenin, and Bergamottin on the Intestinal Carrier-Mediated Transport of Talinolol in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 4840-4845.	2.4	48
105	Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	48
106	Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 93-114.	1.5	46
107	Mathematical modeling of cortisol circadian rhythm and cortisol suppression. <i>European Journal of Pharmaceutical Sciences</i> , 1996, 4, 341-350.	1.9	45
108	Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 237-256.	0.9	45

#	ARTICLE	IF	CITATIONS
109	Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 122-128.	1.4	43
110	Determination of Free Extracellular Concentrations of Piperacillin by Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 369-372.	1.6	42
111	Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. <i>Pharmaceutical Research</i> , 2001, 18, 1310-1314.	1.7	42
112	Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 263-270.	1.1	41
113	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	2.3	41
114	Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP). <i>Journal of Clinical Pharmacology</i> , 2001, 41, 425-434.	1.0	39
115	Single- and Multiple-Dose Pharmacokinetics of Oral Creatine. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 29-37.	1.0	39
116	Potential of Pharmacokinetic Profiling for Detecting Herbal Interactions with Drugs. <i>Clinical Pharmacokinetics</i> , 2008, 47, 383-397.	1.6	39
117	Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 1210-1215.	1.6	38
118	Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 361-373.	2.0	38
119	Isolation and HPLC Quantitative Analysis of Antioxidant Flavonoids from <i>Alternanthera tenella</i> Colla. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2006, 61, 19-25.	0.6	38
120	Disposition of Cefotaxime and its Desacetyl Metabolite in Morbidly Obese Male and Female Subjects. <i>Therapeutic Drug Monitoring</i> , 1986, 8, 189-194.	1.0	37
121	Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl- β -cyclodextrin-Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 335-339.	1.6	37
122	Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 106007.	1.1	37
123	Pharmacokinetic-pharmacodynamic modelling of the in vitro anti-infective effect of piperacillin-tazobactam combinations. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1997, 35, 426-33.	0.3	37
124	A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 22, 123-129.	1.4	36
125	Pharmacokinetic and pharmacodynamic modeling of cetorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 617-625.	2.3	36
126	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisone. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1480-1489.	1.6	36

#	ARTICLE	IF	CITATIONS
127	Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2773-2776.	1.4	36
128	Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2853-2859.	1.6	36
129	High-performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration to rats. <i>Pharmaceutical Research</i> , 1988, 05, 172-177.	1.7	35
130	The use of 2-hydroxypropyl- β -cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. <i>International Journal of Pharmaceutics</i> , 1990, 59, 225-230.	2.6	35
131	Pharmacokinetic-Pharmacodynamic Modeling of Testosterone and Luteinizing Hormone Suppression by Cetrorelix in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 266-274.	1.0	35
132	Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 659-665.	1.0	35
133	Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1313-1331.	1.0	35
134	<i>In vitro</i> pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1866-1880.	1.3	35
135	Pharmacokinetics of Intravenous Immunoglobulin (Gammagard) in Bone Marrow Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 1151-1154.	1.0	34
136	Single-Dose and Steady-State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus [®] or Turbohaler [®] Dry-Powder Inhalers to Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1329-1338.	1.0	34
137	Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 434-441.	1.1	34
138	Relationship Between Serum and Free Interstitial Concentrations of Cefodizime and Cefpirome in Muscle and Subcutaneous Adipose Tissue of Healthy Volunteers Measured by Microdialysis. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 1108-1113.	1.0	33
139	Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form*. <i>Infection</i> , 2005, 33, 22-28.	2.3	33
140	Medications in Space: In Search of a Pharmacologist's Guide to the Galaxy. <i>Pharmaceutical Research</i> , 2019, 36, 148.	1.7	33
141	High-Performance Liquid Chromatographic Assay of Methadone, Phencyclidine, and Metabolites by Postcolumn Ion-Pair Extraction and On-Line Fluorescent Detection of the Counterion with Applications. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 630-635.	1.6	32
142	Electrochemical Chromatographic Determinations of Morphine Antagonists in Biological Fluids, with Applications. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 621-624.	1.6	32
143	Pulmonary targeting of liposomal triamcinolone acetonide phosphate. <i>Pharmaceutical Research</i> , 1996, 13, 1699-1703.	1.7	32
144	Microdialysis as a tool in local pharmacodynamics. <i>AAPS Journal</i> , 2006, 8, E222-E235.	2.2	32

#	ARTICLE	IF	CITATIONS
145	Polymethoxylated Flavones and Other Phenolic Derivates from Citrus in Their Inhibitory Effects on P-Glycoprotein-Mediated Transport of Talinolol in Caco-2 Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2007, 55, 2563-2568.	2.4	32
146	Population Pharmacodynamic Model of Bronchodilator Response to Inhaled Albuterol in Children and Adults With Asthma. <i>Chest</i> , 2008, 134, 981-989.	0.4	32
147	Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3149-3155.	1.4	32
148	Microdialysis of Large Molecules. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3233-3242.	1.6	32
149	Sensitive liquid chromatography assay for the determination of amikacin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1991, 9, 251-254.	1.4	31
150	The Effect of Critical Illness on Drug Distribution. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2030-2036.	0.9	31
151	Simulation-Based Sodium Thiosulfate Dosing Strategies for the Treatment of Calciphylaxis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1155-1159.	2.2	31
152	Pharmacokinetics of <i>para</i> -Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6242-6250.	1.4	31
153	Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics. <i>Pain</i> , 1982, 12, 329-341.	2.0	30
154	Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. <i>Biomedical Applications</i> , 1985, 341, 131-138.	1.7	30
155	Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 704-710.	1.0	30
156	Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 769-778.	1.3	30
157	Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29, a novel aqueous nasal spray. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 125-133.	1.1	30
158	Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development. <i>Clinical Pharmacokinetics</i> , 2019, 58, 545-564.	1.6	30
159	Pharmacokinetics of Morphine and its Surrogates VII: High-Performance Liquid Chromatographic Analyses and Pharmacokinetics of Methadone and its Derived Metabolites in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 1203-1214.	1.6	29
160	Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. <i>Pharmaceutical Research</i> , 1995, 12, 134-137.	1.7	29
161	Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 401-409.	1.3	29
162	Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 453-464.	1.1	28

#	ARTICLE	IF	CITATIONS
163	Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. <i>Pharmaceutical Research</i> , 1991, 08, 263-268.	1.7	28
164	Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. <i>International Journal of Pharmaceutics</i> , 1992, 87, 183-193.	2.6	28
165	AUIC " A General Target for the Optimization of Dosing Regimens of Antibiotics?. <i>Annals of Pharmacotherapy</i> , 1996, 30, 1024-1028.	0.9	28
166	Population Pharmacokinetic Model of Human Insulin Following Different Routes of Administration. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1015-1024.	1.0	28
167	Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. <i>Clinical Chemistry</i> , 1992, 38, 1491-4.	1.5	28
168	PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, S218.	1.5	27
169	A Pharmacokinetic/Pharmacodynamic Approach to Predict Total Prednisolone Concentrations in Human Plasma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 355-372.	0.8	27
170	Determination of Atypical Nonlinear Plasma-Protein-Binding Behavior of Tigecycline Using an In Vitro Microdialysis Technique. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1013-1019.	1.6	27
171	A review of the effects of chronic exercise and physical fitness level on resting pharmacokinetics. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 504-516.	0.3	27
172	PK-PD modelling of the effect of cefaclor on four different bacterial strains. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 218-225.	1.1	26
173	Development and validation of a LC-MS/MS method based on a new 96-well Hybrid-SPE, ϕ -precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 2371-2381.	1.9	26
174	Bioavailability and Metabolism of Mometasone Furoate: Pharmacology versus Methodology. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 383-387.	1.0	26
175	Pharmacokinetic evaluation of β -lactam antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 1989, 24, 407-413.	1.3	25
176	Pharmacokinetics of Dichloroacetate in Adult Patients with Lactic Acidosis. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 416-425.	1.0	25
177	Evaluation of Pulmonary Absorption Using Pharmacokinetic Methods. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2001, 14, 9-17.	1.2	25
178	Electroencephalogram-based pharmacodynamic measures: a review. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 162-184.	0.3	25
179	Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. <i>Biopharmaceutics and Drug Disposition</i> , 1985, 6, 423-432.	1.1	24
180	Coulometric High-Performance Liquid Chromatographic Analysis of Morphine in Biological Fluids. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 1198-1200.	1.6	24

#	ARTICLE	IF	CITATIONS
181	Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. <i>Pharmaceutical Research</i> , 1988, 05, 509-513.	1.7	24
182	Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 893-903.	1.0	24
183	Tissue Penetration of Cefpodoxime and Cefixime in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 564-569.	1.0	24
184	Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5039-5045.	1.4	24
185	Pharmacokinetics of Modified-Release Prednisone Tablets in Healthy Subjects and Patients With Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 326-333.	1.0	24
186	Prediction of <i>in vivo</i> and <i>in vitro</i> infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 197-207.	1.3	24
187	A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1295-1304.	1.3	24
188	Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. <i>Investigational New Drugs</i> , 2019, 37, 364-374.	1.2	24
189	The Lack of Effect of Aerobic Exercise Training on Propranolol Pharmacokinetics in Young and Elderly Adults. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 885-894.	1.0	23
190	Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 160, 119-125.	1.4	23
191	Pharmacokinetic/Pharmacodynamic Modeling of Luteinizing Hormone (LH) Suppression and LH Surge Delay by Cetrorelix after Single and Multiple Doses in Healthy Premenopausal Women. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 243-251.	1.0	22
192	Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 822-831.	1.0	22
193	Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. <i>Neuropharmacology</i> , 2008, 55, 812-818.	2.0	22
194	The <i>Candida albicans</i> phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. <i>Microbiology (United Kingdom)</i> , 2008, 154, 3296-3308.	0.7	22
195	Influence of the Duffy Antigen on Pharmacokinetics and Pharmacodynamics of Recombinant Monocyte Chemoattractant Protein (MCP-1, CCL-2) <i>in Vivo</i> . <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 615-625.	1.0	22
196	Pharmacokinetics of Rimexolone After Intra-articular Administration. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 476-479.	1.0	21
197	Assessment of the Impact of Dosing Time on the Pharmacokinetics/Pharmacodynamics of Prednisolone. <i>AAPS Journal</i> , 2008, 10, 331-41.	2.2	21
198	Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 17-42.	1.1	21

#	ARTICLE	IF	CITATIONS
199	Evaluation of in vitro synergy between vertilmicin and ceftazidime against <i>Pseudomonas aeruginosa</i> using a semi-mechanistic pharmacokinetic/pharmacodynamic model. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 151-160.	1.1	21
200	Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1012-1021.	1.3	21
201	Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 275-283.	1.1	21
202	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.	1.0	20
203	Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 849-860.	2.5	20
204	Pharmacokinetics and Tissue Distribution of Dodeca-2<i>E</i>,4<i>E</i>,8<i>E</i>,10<i>E</i>/<i>Z</i>-tetraenoic Acid Isobutylamides after Oral Administration in Rats. <i>Planta Medica</i> , 2009, 75, 1306-1313.	0.7	20
205	Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 658-664.	1.9	20
206	Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 9S-19S.	1.0	20
207	Population Pharmacokinetic Modeling of the Unbound Levofloxacin Concentrations in Rat Plasma and Prostate Tissue Measured by Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 678-686.	1.4	20
208	Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 85, 57-64.	6.6	20
209	Nonlinear Protein Binding: Not What You Think. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1754-1760.	1.6	20
210	Lack of Clinically Significant In Vitro and In Vivo Interactions between Ranitidine and Sucralfate. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 995-998.	1.6	19
211	In vitro microdialysis sampling of docetaxel. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 36, 807-813.	1.4	19
212	The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 149-157.	0.5	19
213	Clinical Pharmacokinetics of Meropenem and Biapenem in Bile and Dosing Considerations for Biliary Tract Infections Based on Site-Specific Pharmacodynamic Target Attainment. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5609-5615.	1.4	19
214	Protein Binding of Rifapentine and Its 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4904-4910.	1.4	19
215	Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant <i>Staphylococcus aureus</i> using minimum inhibitory concentration and time-kill curve based approaches. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 60-67.	1.1	19
216	Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. <i>Die Pharmazie</i> , 1995, 50, 610-3.	0.3	19

#	ARTICLE	IF	CITATIONS
217	High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1990, 8, 67-71.	1.4	18
218	Simultaneous assay of propranolol, diltiazem and metabolites of diltiazem in human plasma by liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1990, 8, 535-539.	1.4	18
219	A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against <i>Candida</i> spp. in vitro. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 369-374.	1.1	18
220	Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2967-2973.	1.2	18
221	Potential of ceftazidime by avibactam against β -lactam-resistant <i>Pseudomonas aeruginosa</i> in an in vitro infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw535.	1.3	18
222	Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1948-1956.	1.6	18
223	Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults. <i>Clinical Pharmacokinetics</i> , 2019, 58, 927-941.	1.6	18
224	Rapid analysis of ranitidine in biological fluids and determination of its erythrocyte partitioning. <i>Biomedical Applications</i> , 1986, 381, 385-391.	1.7	17
225	Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 835-836.	1.6	17
226	A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 127-147.	0.6	17
227	Variability in Response to Cardiovascular Drugs. <i>Current Clinical Pharmacology</i> , 2006, 1, 35-46.	0.2	17
228	Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 96-97.	1.1	17
229	A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 449-455.	1.1	17
230	Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 477-483.	1.3	17
231	Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2008, 46, 617-626.	0.3	17
232	Clinical PK/PD modelling as a tool in drug development of corticosteroids. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1997, 35, 481-8.	0.3	17
233	Pharmacokinetic/Pharmacodynamic Consequences of Space Flight. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 684-691.	1.0	16
234	Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 494-497.	1.1	16

#	ARTICLE	IF	CITATIONS
235	AAPS-FDA workshop white paper: Microdialysis principles, application, and regulatory perspectives report from the Joint AAPS-FDA Workshop, November 4-5, 2005, Nashville, TN. AAPS Journal, 2007, 9, E48-E59.	2.2	16
236	Population Pharmacokinetics and Pharmacodynamics of Inhaled Ciclesonide and Fluticasone Propionate in Patients With Persistent Asthma. Journal of Clinical Pharmacology, 2010, 50, 1118-1127.	1.0	16
237	Experimental design and modelling approach to evaluate efficacy of β -lactam/ β -lactamase inhibitor combinations. Clinical Microbiology and Infection, 2018, 24, 707-715.	2.8	16
238	Simultaneous determination of propranolol and 4-hydroxypropranolol enantiomers after chiral derivatization using reversed-phase high-performance liquid chromatography. Biomedical Applications, 1990, 527, 351-359.	1.7	15
239	Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. Pharmaceutical Research, 1994, 11, 1056-1059.	1.7	15
240	An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci, 2000, 2, 28-37.	1.3	15
241	Clinical and pharmacological aspects of accidental triamcinolone acetonide overdose: a case study. Netherlands Journal of Medicine, 2000, 56, 12-16.	0.6	15
242	Pharmacokinetics of Luteolin and Metabolites in Rats. Natural Product Communications, 2008, 3, 1934578X0800301.	0.2	15
243	Repeated pre-exposure to tobacco smoke potentiates subsequent locomotor responses to nicotine and tobacco smoke but not amphetamine in adult rats. Pharmacology Biochemistry and Behavior, 2011, 100, 109-118.	1.3	15
244	Largazole Pharmacokinetics in Rats by LC-MS/MS. Marine Drugs, 2014, 12, 1623-1640.	2.2	15
245	Predicting Pediatric Age-Matched Weight and Body Mass Index. AAPS Journal, 2014, 16, 1372-1379.	2.2	15
246	Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs of Today, 2014, 50, 15.	0.7	15
247	Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. International Journal of Clinical Pharmacology and Therapeutics, 2005, 43, 117-122.	0.3	15
248	Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. International Journal of Clinical Pharmacology and Therapeutics, 1999, 37, 367-76.	0.3	15
249	Pitfalls in pharmacokinetic multicompartment analysis. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 247-260.	0.6	14
250	Pharmacokinetic/Pharmacodynamic Modeling of Total Lymphocytes and Selected Subtypes After Oral Budesonide. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 441-459.	0.8	14
251	Measurement of Voriconazole Activity against <i>Candida albicans</i> , <i>C. glabrata</i> , and <i>C. parapsilosis</i> Isolates Using Time-Kill Methods Validated by High-Performance Liquid Chromatography. Antimicrobial Agents and Chemotherapy, 2007, 51, 2985-2987.	1.4	14
252	HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 61-69.	0.6	14

#	ARTICLE	IF	CITATIONS
253	Development and validation of a HPLC-MS/MS method for the determination of phytolaccagenin in rat plasma and application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 82-88.	1.4	14
254	Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2509-2514.	1.6	14
255	Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 190-196.	1.1	14
256	A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against <i>Pseudomonas aeruginosa</i> . <i>Clinical Microbiology and Infection</i> , 2019, 25, 904.e9-904.e16.	2.8	14
257	Pharmacokinetic profile of cefaclor. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1997, 35, 374-80.	0.3	14
258	Local Treatment of Respiratory Infections with Antibiotics. <i>Drug Intelligence & Clinical Pharmacy</i> , 1987, 21, 322-329.	0.4	13
259	High-performance liquid chromatographic determination of conjugated estrogens in tablets. <i>Journal of Chromatography A</i> , 1988, 450, 414-419.	1.8	13
260	Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. <i>European Respiratory Journal</i> , 2001, 17, 157-158.	3.1	13
261	Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate after Single and Multiple Administration in Healthy Subjects and Patients. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 536-541.	1.0	13
262	Measuring drug distribution in the critically ill patient. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 22-26.	6.6	13
263	Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 240-254.	1.5	13
264	Pharmacometrics in Bacterial Infections. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 229-258.	0.2	13
265	Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1996, 34, 482-8.	0.3	13
266	Comparison of skin permeability for three diclofenac topical formulations: an in vitro study. <i>Die Pharmazie</i> , 2014, 69, 27-31.	0.3	13
267	Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1985, 3, 566-573.	1.4	12
268	A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog. <i>Pharmaceutical Research</i> , 1990, 07, 879-883.	1.7	12
269	A selective HPLC/RIA for the determination of budesonide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998, 17, 1235-1242.	1.4	12
270	Population Pharmacokinetics of Digoxin in Egyptian Pediatric Patients: Impact of One Data Point Utilization. <i>American Journal of Therapeutics</i> , 2002, 9, 492-498.	0.5	12

#	ARTICLE	IF	CITATIONS
271	Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. <i>The International Journal of Clinical Pharmacology, and Toxicology</i> , 1992, 30, 317-24.	0.1	12
272	Pharmacokinetics and pharmacodynamics of cloprednol. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1996, 34, 1-5.	0.3	12
273	Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. <i>European Journal of Clinical Pharmacology</i> , 1986, 31, 363-365.	0.8	11
274	HPLC analysis of buprenorphine in plasma and urine using coulometric detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1987, 5, 303-308.	1.4	11
275	Increased Erythrocyte and Protein Binding of Codeine in Patients with Sickle Cell Disease. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 1112-1117.	1.6	11
276	Pharmacokinetic/Pharmacodynamic Evaluation of the NHE Inhibitor Eniporide. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 139-148.	1.0	11
277	Comparative Target Site Pharmacokinetics of Immediate- and Modified-Release Formulations of Cefaclor in Humans. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 403-411.	1.0	11
278	Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 904-908.	1.5	11
279	Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 130-135.	0.6	11
280	Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 352-355.	0.7	11
281	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 413-419.	1.1	11
282	Concentration-response studies and modelling of the pharmacodynamics of linezolid: <i>Staphylococcus aureus</i> versus <i>Enterococcus faecium</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 54-60.	1.1	11
283	Role of Divalent Metal Ions in Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3409-3414.	1.6	11
284	Pharmacokinetics of Oxytetracycline in the Giant Danio (<i>Devario aequipinnatus</i>) following bath immersion. <i>Aquaculture</i> , 2019, 498, 12-16.	1.7	11
285	A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1991, 9, 761-767.	1.4	10
286	A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat. <i>Pharmaceutical Research</i> , 1991, 08, 1180-1185.	1.7	10
287	Pharmacokinetic/Pharmacodynamic Modeling of Cortisol Suppression after Oral Administration of Fluocortolone. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 311-314.	1.0	10
288	Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 970-975.	1.4	10

#	ARTICLE	IF	CITATIONS
289	Erythrocyte binding of cephalosporins. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 129-131.	1.2	10
290	Principles of Applied Pharmacokineticâ€“Pharmacodynamic Modeling. , 2014, , 63-79.		10
291	Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization. <i>AAPS Journal</i> , 2017, 19, 334-342.	2.2	10
292	Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 704-716.	1.0	10
293	A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702166.	3.1	10
294	Comparative Target Site Pharmacokinetics of Immediate- and Modified-Release Formulations of Cefaclor in Humans. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 403-411.	1.0	10
295	Cortical-Evoked Potentials and Saliva Levels as Basis for the Comparison of Pure Analgesics to Analgesic Combinations. <i>Pharmacology</i> , 1982, 25, 227-236.	0.9	9
296	In vivo-in vitro correlations of salicylate saliva levels and continuous flow cell dissolution rates. <i>International Journal of Pharmaceutics</i> , 1983, 15, 167-175.	2.6	9
297	The Influence of Formulation on the Dissolution Profile of Diclofenac Sodium Tablets. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 1103-1109.	0.9	9
298	Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1084-1091.	1.4	9
299	Dose Optimization Based on Pharmacokinetic-Pharmacodynamic Modeling. , 2019, , 79-120.		9
300	Population pharmacokinetics of digoxin in Korean patients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2000, 38, 291-297.	0.3	9
301	A Selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. <i>Biomedical Chromatography</i> , 1992, 6, 283-286.	0.8	8
302	Population pharmacokinetic/pharmacodynamic modeling of cetorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. <i>Pharmaceutical Research</i> , 2000, 17, 328-335.	1.7	8
303	Bioavailability and Metabolism of Mometasone Furoate: Pharmacology versus Methodology. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 383-387.	1.0	8
304	Intranasal Loteprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 510-519.	1.0	8
305	Development and Validation of an HPLC Method for Oxytocin in Ringer's Lactate and its Application in Stability Analysis. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2006, 29, 2353-2365.	0.5	8
306	Toxicological and Pharmacokinetic Evaluation of Concomitant Intake of Grapefruit Juice and Simvastatin in Rats after Repeated Treatment over 28 Days. <i>Planta Medica</i> , 2009, 75, 1196-1202.	0.7	8

#	ARTICLE	IF	CITATIONS
307	Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole–Candida interactions. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 240-245.	1.1	8
308	Absolute/Relative Bioavailability and Metabolism of Dodeca-2 <i>E</i> ,4 <i>E</i> ,8 <i>Z</i> ,10 <i>E</i> / <i>Z</i> -Tetraenoic Acid Isobutylamides (Tetraenes) after Intravenous and Oral Single Doses to Rats. <i>Planta Medica</i> , 2011, 77, 1794-1799.	0.7	8
309	Pharmacodynamic In Vitro Models to Determine the Effect of Antibiotics. , 2014, , 81-112.		8
310	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 1-64.	0.2	8
311	Quantitation of the impact of <i>CYP3A5</i> A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 387-394.	0.8	8
312	Pharmacokinetic Evaluation of Avicularin Using a Model-Based Development Approach. <i>Planta Medica</i> , 2015, 81, 373-381.	0.7	8
313	Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. <i>Planta Medica</i> , 2015, 81, 1121-1127.	0.7	8
314	Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 997-1006.	2.0	8
315	Gastric-acid-mediated drug–drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies. <i>Drug Discovery Today</i> , 2019, 24, 845-857.	3.2	8
316	Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration. <i>Die Pharmazie</i> , 1997, 52, 529-32.	0.3	8
317	Development of an Oral Drug Formulation for Dichloroacetate and Thiamine. <i>Drug Development and Industrial Pharmacy</i> , 1994, 20, 2425-2437.	0.9	7
318	KA 672-HCl, a Neuronal Activator Against Dementia: Tolerability, Safety, and Preliminary Pharmacokinetics after Single and Multiple Oral Doses in Healthy Male and Female Volunteers. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 373-381.	1.0	7
319	Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. <i>Therapeutics and Clinical Risk Management</i> , 2010, Volume 6, 485-495.	0.9	7
320	Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 327-333.	1.1	7
321	Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development. , 2016, , 185-217.		7
322	Population Pharmacokinetics of Methotrexate in Egyptian Children with Lymphoblastic Leukemia. <i>Pharmacology & Pharmacy</i> , 2013, 04, 139-145.	0.2	7
323	What is the best marker for inhaled corticosteroid safety?. <i>Allergy and Asthma Proceedings</i> , 2005, 26, 89-93.	1.0	7
324	Evaluation of free tissue concentrations of fleroxacin after oral administration. <i>Pharmaceutical Research</i> , 1990, 07, 422-424.	1.7	6

#	ARTICLE	IF	CITATIONS
325	A Reversed Phase Liquid Chromatographic Method for the Determination of Codeine in Biological Fluids with Applications. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1993, 16, 2325-2334.	0.9	6
326	Codeine Disposition in Sickle Cell Patients Compared With Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 811-815.	1.0	6
327	Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 110-121.	1.9	6
328	Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106405.	1.1	6
329	Evaluation of the Effects of <i>Maytenus ilicifolia</i> on the Activities of Cytochrome P450 3A and P-glycoprotein. <i>Current Drug Metabolism</i> , 2020, 21, 281-290.	0.7	6
330	Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004, 42, 504-511.	0.3	6
331	Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure. <i>Die Pharmazie</i> , 2010, 65, 417-20.	0.3	6
332	Pharmacodynamic Aspects of Systemic Drug Delivery. <i>Drug Development and Industrial Pharmacy</i> , 1994, 20, 485-502.	0.9	5
333	Pharmacodynamic Evaluation of Codeine Using Tooth Pulp Evoked Potentials. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 1126-1131.	1.0	5
334	Risk-Benefit Value of Inhaled Corticosteroids. <i>Chest</i> , 2003, 123, 430S-431S.	0.4	5
335	Influence of <i>CYP3A5</i> 6986A>G and <i>ABCB1</i> 3435C>T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 67-78.	0.8	5
336	Simultaneous Retrodialysis by Calibrator for Rapid In Vivo Recovery Determination in Target Site Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2259-2265.	1.6	5
337	Tobacco smoke exposure enhances reward sensitivity in male and female rats. <i>Psychopharmacology</i> , 2021, 238, 845-855.	1.5	5
338	In vitro recovery of triamcinolone acetonide in microdialysis. <i>Die Pharmazie</i> , 2000, 55, 659-62.	0.3	5
339	Extent of Drug Absorption at the Time of Peak Plasma Concentration in an Open One-Compartment Body Model with First-order Absorption. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 462.	1.6	4
340	Theophylline Absorption and Gastric Emptying after Partial Gastrectomy in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 968-969.	1.6	4
341	Systematic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 303-306.	1.9	4
342	Thromboelastographic and pharmacokinetic profiles of micro- and macro-emulsions of propofol in swine. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 269-277.	1.1	4

#	ARTICLE	IF	CITATIONS
343	Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. Annals of the New York Academy of Sciences, 2010, 1207, 134-142.	1.8	4
344	Grapefruitâ€“medication interactions. Cmaj, 2013, 185, 507.1-507.	0.9	4
345	Electroencephalogram effects of armodafinil: Comparison with behavioral alertness. Journal of Clinical Pharmacology, 2013, 53, 1058-1071.	1.0	4
346	Quantitative determination of armodafinil in human plasma by liquid chromatographyâ€“electrospray mass spectrometry: Application to a clinical study. Biomedical Chromatography, 2018, 32, e4342.	0.8	4
347	Development and Validation of a Sensitive UFLCâ€“MS/MS Method for Quantification of Quercitrin in Plasma: Application to a Tissue Distribution Study. ACS Omega, 2019, 4, 3527-3533.	1.6	4
348	Pharmacokinetics and Determination of Tumor Interstitial Distribution of a Therapeutic Monoclonal Antibody Using Large-Pore Microdialysis. Journal of Pharmaceutical Sciences, 2021, 110, 3061-3068.	1.6	4
349	Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics. GMS Infectious Diseases, 2020, 8, Doc17.	0.5	4
350	Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. Die Pharmazie, 2000, 55, 223-7.	0.3	4
351	Pharmacokinetics of Ranitidine after Partial Gastrectomy in Dogs. Journal of Pharmaceutical Sciences, 1991, 80, 1034-1036.	1.6	3
352	Microdialysis of Triamcinolone Acetonide in Rat Muscle. Journal of Pharmaceutical Sciences, 2003, 92, 394-397.	1.6	3
353	The Effect of Protein Binding on Adrenal Suppression Potential of Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology, 2006, 117, S94.	1.5	3
354	Extended Stability of Oxytocin in Ringer's Lactate Solution at 4Â° and 25Â°C. Hospital Pharmacy, 2006, 41, 437-441.	0.4	3
355	Enhanced in vitro activity of tigecycline in the presence of chelating agents. International Journal of Antimicrobial Agents, 2018, 51, 799-802.	1.1	3
356	Determination of Dermal Pharmacokinetics by Microdialysis Sampling in Rats. Current Protocols in Pharmacology, 2019, 85, e58.	4.0	3
357	Antipyrine - new light on an old drug. Pharmaceutical Research, 1984, 01, 225-229.	1.7	2
358	Population Pharmacokinetics of Eniporide and Its Metabolite in Healthy Subjects and Patients With Acute Myocardial Infarction. Journal of Clinical Pharmacology, 2005, 45, 631-639.	1.0	2
359	Application of Two-Point Assay of Digoxin Serum Concentration in Studying Population Pharmacokinetics in Egyptian Pediatric Patients with Heart Failure: Does It Make Sense?. American Journal of Therapeutics, 2005, 12, 320-327.	0.5	2
360	Pharmacokinetics and Pharmacodynamics of Biotech Drugs. , 2005, , 145-172.		2

#	ARTICLE	IF	CITATIONS
361	Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 145-157.	1.1	2
362	PK/PD Approaches. , 2018, , 1-23.		2
363	PK/PD Approaches. , 2019, , 1-23.		2
364	Drug-Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1289-1291.	2.3	2
365	Plasma indospicine and 3-nitropropionic acid in ponies fed creeping indigo: Comparison with results from an episode of presumptive creeping indigo toxicosis. <i>Equine Veterinary Journal</i> , 2022, 54, 145-152.	0.9	2
366	Pharmacokinetic Aspects of Intra-articular Administration of Glucocorticoids. , 1989, , 474-481.		2
367	Evoked potentials as objective parameters for the analgesic response of weak analgesics. <i>Advances in Neurology</i> , 1982, 32, 375-81.	0.8	2
368	Effects of Truncal Vagotomy and Partial Gastrectomy on the Pharmacokinetics of Propranolol Enantiomers in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 292-294.	1.6	1
369	Response to the Commentary on "Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs". <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1067-1068.	1.6	1
370	Ciclesonide in the Management of Asthma. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2133.	0.1	1
371	Suppression of ciprofloxacin-induced resistant <i>Pseudomonas aeruginosa</i> in a dynamic kill curve system. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 519-524.	1.1	1
372	Microdialysis in Antibiotic Research. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 103-126.	0.2	1
373	Water Soluble Complexes of a Brain-Targeted Drug Delivery System. , 1988, , 399-405.		1
374	Novel Formulations of Cetrorelix Acetate in Healthy Men: Pharmacodynamic Effects and Noncompartmental Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 995-1001.	1.0	1
375	Effect of high doses of glucocorticoids on the kinetics of human white blood cells in vivo. <i>Medizinische Klinik</i> , 1988, 83, 159-63.	0.5	1
376	Systemic absorption of prednicarbate after dermal, oral and pulmonary administration. <i>European Journal of Pharmacology</i> , 1990, 183, 2134.	1.7	0
377	Prednicarbate after Different Forms of Administration. <i>Current Problems in Dermatology</i> , 1993, 21, 147-156.	0.8	0
378	SC7 receptor-based PK/PD model for corticosteroids. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 92.	1.9	0

#	ARTICLE	IF	CITATIONS
379	FC5 PK/PD based characterization of pulmonary targeting. European Journal of Pharmaceutical Sciences, 1994, 2, 102.	1.9	0
380	P140 a selective HPLC/RIA assay for budesonide in biological fluids. European Journal of Pharmaceutical Sciences, 1994, 2, 153.	1.9	0
381	Disposition and Blood Cell Effects of Prednisolone and Methylprednisolone. Clinical Pharmacology and Therapeutics, 1996, 59, 207-207.	2.3	0
382	Clinical Trials and Dipyridamole Formulation Selection. Cerebrovascular Diseases, 2007, 23, 72-73.	0.8	0
383	Response to Dr. Blum. Journal of Clinical Pharmacology, 2007, 47, 537-537.	1.0	0
384	Pharmacokinetics I: PK-PD approaches - antibiotic drug development. , 2010, , 143-155.		0
385	Methodologies for Protein Binding Determination in Anti-infective Agents. Methods in Pharmacology and Toxicology, 2016, , 109-125.	0.1	0
386	Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight. , 2019, , 1-30.		0
387	PK/PD modeling of hormone effects by cetorelix. BMC News and Views, 2002, 2, .	0.0	0
388	Drug Interactions of Grapefruit and Other Citrus_What Have We Learned?. Drugs and the Pharmaceutical Sciences, 2006, , 147-190.	0.1	0
389	Pharmacokinetics of Botanical Products. Drugs and the Pharmaceutical Sciences, 2006, , 205-244.	0.1	0
390	Evaluation of the effect of grapefruit juice and its components on P-glycoprotein activity. Planta Medica, 2006, 72, .	0.7	0
391	Functional Role of the Chemokine Binding Duffy Antigen Receptor Complex (DARC) in Human Inflammation In Vivo.. Blood, 2006, 108, 20-20.	0.6	0
392	Exploring mechanisms of grapefruit juice drug interactions and its potential toxicity. Planta Medica, 2007, 73, .	0.7	0
393	Pharmacokinetic profiling of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides in rats using liquid chromatography tandem mass spectrometry. Planta Medica, 2008, 74, .	0.7	0
394	Bioavailability of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides after oral administration in rats and distribution in various tissues. Planta Medica, 2009, 75, .	0.7	0
395	Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs. Infectious Disorders - Drug Targets, 2011, 11, 157-166.	0.4	0
396	Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight. , 2019, , 1-30.		0

#	ARTICLE	IF	CITATIONS
397	PK/PD Approaches. , 2020, , 1047-1069.		0
398	Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight. , 2022, , 135-164.		0